AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
As of today, AbbVie(ABBV) shares are valued at $250.09. The company's market cap stands at 446.85B, with a P/E ratio of 69.30 and a dividend yield of 2.79%.
During the trading session on 2026-08-11, AbbVie(ABBV) shares reached a daily high of $250.76 and a low of $247.18. At a current price of $250.09, the stock is +1.2% higher than the low and still -0.3% under the high.
Trading volume for AbbVie(ABBV) stock has reached 4.37M, versus its average volume of 5.81M.
The stock's 52-week range extends from a low of $190.75 to a high of $267.47.
The stock's 52-week range extends from a low of $190.75 to a high of $267.47.
ABBV News
Key Points AbbVie leverages a strong specialty drug portfolio to offset the loss of exclusivity for its former top-selling products. CVS Health continues to e...
AbbVie (NYSE:ABBV) said the FDA has accepted for review a supplemental Biologics License Application for BOTOX Cosmetic to treat masseter muscle prominence in t...
Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...
Analyst ratings
75%
of 32 ratingsMore ABBV News
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...
Key Points AbbVie has been willing to supplement its new drug pipeline through acquisitions. It plans to pay $10.6 billion to purchase clinical-stage biotech...
Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on AbbVie (ABBV) to $260 from $246 and keeps an Outperform rating on the shares. Unlock...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...
The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie is now the #114 analyst pick,...
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, AbbVie Inc (Symbol: ABBV) has taken over the #60 sp...
Key Points AbbVie posted solid second-quarter financial results, led by its two most important products, Skyrizi and Rinvoq. The company's portfolio and pipel...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.